Pediatric exclusivity and the six months it adds before generics

On Feb. 22, 2002, FDA granted six months of pediatric exclusivity for two of the most widely used cholesterol drugs in the country, atorvastatin and simvastatin, after their makers studied them in children with high cholesterol. The two entries sit next to each other on FDA's spreadsheet of pediatric exclusivity determinations², a list the agency updates each time it grants one.

That list now runs to 336 rows. On the page that hosts it¹, FDA counts 354 exclusivity determinations covering 321 approved active moieties, with the latest version dated July 2026. GxRadar matched the spreadsheet against the 46 molecules on our drug pages and found 26 of them on it, from gabapentin in February 2000 to tadalafil in November 2017.

For generic manufacturers, those grants matter because pediatric exclusivity rarely stands alone. It adds six months to protections a brand already holds, including patents and the other exclusivity periods in the Orange Book. This piece explains how FDA asks for pediatric studies, what the extra six months attach to, and what the agency's records show about how often the reward is paid.

How a written request works

Section 505A of the Federal Food, Drug, and Cosmetic Act holds the incentive, codified at 21 U.S.C. 355a⁵. Congress added it in the Food and Drug Administration Modernization Act of Nov. 21, 1997, and renewed and rewrote it in the Best Pharmaceuticals for Children Act¹¹ of Jan. 4, 2002, usually shortened to BPCA.

FDA starts the process. When the agency decides that information about a drug's use in children "may produce health benefits in that population," it sends the brand sponsor a written request describing the studies it wants and a timeframe for finishing them. The sponsor has 180 days to say whether it will do the work. Nothing obliges it to agree. FDA's list of written requests issued³ says plainly that conducting the studies "is voluntary."

Once the study reports arrive, the statute gives FDA 180 days to accept or reject them, and it narrows the question. The agency's "only responsibility," the law says⁵, is to decide whether the studies "fairly respond to the written request" and were run and reported to accepted scientific standards. A study does not have to show the drug works in children. Since 2007 the statute has instead required FDA to order the drug's labeling to describe the pediatric results, whether they were positive, negative or inconclusive.

What the six months attach to

Pediatric exclusivity has no clock of its own. Under section 505A(b) and (c)⁵, it lengthens whatever periods already block a generic. FDA's plain-language summary of patents and exclusivity⁶ describes it as "6 months added to existing Patents/Exclusivity." The statute spells out each adjustment.

Two limits shape how much the reward is worth. The extension applies to a patent only in the two situations in the last rows of the table. A generic company that wins its paragraph IV challenge is outside both. And under the same section, FDA may not extend a period if its determination comes "later than 9 months prior to the expiration of such period," which pushes sponsors to finish studies well before a patent runs out.

Congress also protected the generic company that filed first. If the six months overlap a first filer's 180-day exclusivity, subsection (m)⁵ extends the 180-day period by the number of days lost to the overlap.

What FDA's lists show

FDA publishes two spreadsheets that, read together, show the program's rhythm. One lists every approved active moiety that received a written request since June 1998. The other lists grants. GxRadar grouped both by period; the latest grant on the July 2026 list is dated May 18, 2026.

Sources: FDA written request list dated Aug. 4, 2026⁴ and FDA exclusivity list dated July 2026². Grants lag requests by years, because studies take time, so the columns do not pair up row by row.

GxRadar's drug list shows the early rush. Grants for metformin, fluoxetine, famotidine, omeprazole, lisinopril, amlodipine, montelukast, sertraline and losartan all date from 2000 to early 2002. Later grants include rosuvastatin in July 2009, clopidogrel in January 2011 and duloxetine in July 2012.

Current data still carry the reward. In the Orange Book data files FDA posted in October 2026, GxRadar counted 603 distinct patents with a companion "*PED" entry, the code FDA uses for a patent's pediatric extension, spread across 182 brand applications. The same exclusivity file⁷ lists unexpired PED entries on 79 applications. FDA's 2026 Orange Book⁸ defines the PED code simply as "pediatric exclusivity."

Labels that changed

For decades, most drugs were never tested in children, which is why the program exists. FDA tracks the result in a pediatric labeling changes spreadsheet⁹ that lists 1,437 labeling changes from February 1998 to May 2026. Of those, 277 came from BPCA studies alone and 137 from studies that served BPCA and the Pediatric Research Equity Act together. Another 937 were driven by the 2003 equity act¹² alone, which can require pediatric studies for some new drugs without paying any exclusivity.

Congress originally put a sunset on the incentive. The 2012 Food and Drug Administration Safety and Innovation Act struck the provision that had limited grants to written requests issued on or before Oct. 1, 2012, according to the statutory notes⁵, which made the program permanent.

Reading the Orange Book for PED entries

For anyone trying to work out when a generic can launch, the PED code is a reminder to add six months. FDA's paragraph IV certification list¹⁰ warns that its patent expiration column "does not reflect any pediatric exclusivity" for the brand. GxRadar's guides to the Hatch-Waxman Act and to tentative approvals explain why a generic can be approved on paper and still wait. A pharmacist can say whether a generic version is stocked yet.

The six-month tails keep arriving. Among the 603 patents with a PED entry in the October 2026 files, 89 have pediatric extension dates that fall in 2027, the largest number for any single year in the file.